Semax Peptide Evidence and Its 2026 HHS Compounding Status

Semax is a synthetic peptide registered in Russia as nasal drops for neurological uses. Small Russian studies reported changes in stroke recovery, optic nerve disease, and brain imaging, but the research does not establish that Semax improves focus, memory, anxiety, or attention-deficit/hyperactivity disorder (ADHD). The U.S. Food and Drug Administration (FDA) has not approved Semax. A 2026 federal draft policy provides limited enforcement discretion for certain intranasal compounded products while the FDA continues its review.¹

The Human Evidence for Semax

Semax is the peptide sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is an analogue of a fragment of adrenocorticotropic hormone (ACTH), a hormone involved in the body’s stress response. The FDA briefing describes Semax as a registered drug in Russia that is supplied as nasal drops.¹

A 2022 review of peptide development in Russia classified Semax as a nootropic drug registered in the Russian Federation.² That classification describes its status in Russia. It does not establish FDA approval or prove that Semax improves cognition.

Most human research has examined neurological conditions rather than everyday focus or memory. The published record includes small studies involving stroke, optic nerve disease, motor neuron disease, and brain imaging in healthy adults.

The stroke and optic nerve studies reported favorable findings, but their designs make the size and reliability of the effects difficult to determine. The ALS study found no effect on disease course. The imaging study measured brain activity without showing that participants thought more clearly or performed better.

A change in a brain scan or blood marker is a biological observation. It does not establish better memory, concentration, or daily function. Your physician would look for a clinical outcome that matches the reason you are considering treatment.

One marker should not set a protocol by itself. Thyroid, hormone, and inflammation markers can form a broader pattern when your physician reads them alongside your symptoms and medical history.

Cognitive Claims and ADHD

The available human studies do not show that Semax treats ADHD. The FDA did not evaluate Semax for ADHD because its review found no literature supporting that use.¹

The healthy-volunteer study found a change in the brain’s default mode network, which is active during rest and internal thought.⁷ It did not test attention, work performance, memory, or ADHD symptoms. You cannot use that scan result to predict how Semax would affect your concentration.

Animal research provides a possible biological explanation for some cognitive claims. In rats, intranasal Semax increased BDNF protein in part of the forebrain within hours.⁸ BDNF is involved in neuronal function, but a rat protein change does not establish a treatment effect in people.

Poor focus can also reflect sleep disruption, thyroid dysfunction, hormone changes, stress, insulin problems, or nutrient deficiencies. A physician can work through those causes before you pursue an unapproved peptide. The same principle applies when you are trying to understand persistent brain fog. Symptoms provide the starting point. Your labs and medical history help identify the cause.

A 55+ biomarker panel can place thyroid, hormone, and inflammation findings beside your symptoms. The physician review determines whether those results form a pattern that needs treatment.

The FDA Review of Semax

The FDA concluded that evidence was insufficient for the three uses it reviewed. Those uses were cerebral ischemia, migraine, and trigeminal neuralgia.¹

The FDA identified roughly 550 people who had received Semax intranasally across the references it reviewed. The group included healthy adults, adults with medical conditions, and children. The FDA also found that most references did not discuss adverse events, which limits conclusions about safety.¹

The FDA found no human pharmacokinetic studies for any route.¹ Pharmacokinetics describes how a substance is absorbed, distributed, metabolized, and removed. Without those data, a physician has less information about exposure and variability between people.

The FDA also found no safety data for subcutaneous Semax.¹ If you see injectable Semax sold online, no human safety record covers that route. The reviewed human record involved intranasal exposure, and the HHS draft policy is limited to intranasal Semax free base.

FDA reviewers identified several safety concerns. These included a possible antithrombotic effect, which could affect bleeding risk or interact with anticoagulant medication. The agency also noted immunogenicity and peptide aggregation concerns.¹

In mice, Semax increased amphetamine-induced dopamine release. The FDA described this as concerning for possible abuse potential, although the cited signal did not establish abuse in people.¹ Your medication list, bleeding history, and reason for considering Semax all belong in a physician review before any treatment decision.

The Federal Compounding Policy

An October 2026 draft policy describes limited enforcement discretion for certain compounded peptide products. The policy does not approve Semax or add it to the 503A bulks list.^9,10

The U.S. Department of Health and Human Services (HHS) policy lists Semax free base for intranasal use as a single active ingredient. Semax is one of six peptides covered under the draft when every stated condition is met.¹⁰

Those conditions include a patient-specific prescription and production by a qualifying compounder. The source manufacturer must be identified and registered, and the bulk substance must have a valid certificate of analysis covering identity, purity, potency, and specified contaminants. The compounder must also report serious adverse events and product-quality problems through the required channels.¹⁰

The policy applies to state-licensed pharmacies, federal facilities, and licensed physicians under the circumstances HHS describes. It does not cover research-use-only products, online peptide sellers, blends, or injectable Semax. Some online sellers market Semax combined with Selank, which the HHS draft does not list.^1,10 Our comparison of how Semax and Selank differ sets out the evidence and policy record for each. Compounded drugs are not FDA-approved, so the FDA does not review their safety, effectiveness, or quality before marketing.^9,10

HHS cited an intranasal record covering several hundred people without a reported adverse outcome. The FDA found that most references did not report adverse events either way.^1,10 Missing reports cannot establish the absence of side effects.

The draft remains open to public comment and is not binding on HHS or the public.⁹ HHS may revise the policy if a safety signal or product-quality problem emerges.¹⁰ You can review the broader policy context and the other five named substances on our page about peptide legality and federal policy.

Semax Safety and Product Quality

Semax safety cannot be separated from the route, source, and medical context. The human record reviewed by the FDA involved intranasal use, while injection safety data were absent.¹

The possible blood-thinning effect deserves attention if you take an anticoagulant or have an existing bleeding risk. A physician should review those factors before deciding whether Semax belongs in your care. The mouse dopamine signal also warrants caution, although it does not prove abuse potential in humans.¹

Product quality creates another variable. The HHS conditions require documentation of identity, purity, potency, and contaminants from a qualifying source.¹⁰ A research-use-only vial bought online does not fall within the draft policy.

If peptide therapy is appropriate for you, medical review should connect the peptide to a defined symptom, relevant labs, current medications, and a follow-up plan. You can read more about physician-guided peptide therapy.

A fixed peptide protocol gives every person the same answer. A physician-built plan starts with your labs, current medications, existing conditions, and treatment goal, then uses follow-up testing to adjust the plan.

Semax and Anti-Doping Rules

Semax is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List, but an unnamed peptide can still create risk for an athlete. The U.S. Anti-Doping Agency (USADA) 2027 advisory states that peptides are addressed within category S0 and urges utmost caution even when a peptide is absent from Global DRO or the WADA list.¹¹

If you compete under anti-doping rules, the absence of the name Semax from a list does not provide a clearance. Raise your anti-doping status with your physician before any peptide is prescribed.

The Opt Take on Semax

Poor focus or memory gets a workup of sleep, thyroid, hormones, and inflammation before any peptide enters the conversation. At Opt Health, a physician interprets those findings against your symptoms, existing conditions, current medications, and goals. Every lab we order gets read by a physician before anyone is offered a treatment.

The starting panel covers 55+ biomarkers and can be completed at home or at a partner lab. Your 1:1 physician review turns those results into a personalized plan. One marker is a data point. Related findings across sleep, thyroid, hormones, and inflammation can reveal a pattern that changes the next step.

A full panel and physician consultation repeat every 3 to 4 months. Your physician can see what changed and adjust the plan around the new results. Membership is required to receive treatment because continuity makes that follow-up possible. The care team is also available by chat 7 days a week.

Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.

Frequently Asked Questions

This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.